Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.68 |
| ▸ | PDE1A | P54750 | 6/20 | 0.68 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.68 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | PDE6A | P16499 | 2/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.65 |
| ▸ | PDE6D | O43924 | 1/20 | 0.65 |
| ▸ | PDE9A | O76083 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | PDE6G | P18545 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | PDE6B | P35913 | 1/20 | 0.65 |
| ▸ | PDE6C | P51160 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218943 | 0.98 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12822873 | 0.96 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL18184293 | 0.96 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL973032 | 0.95 | PDE5A (0.68) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12823651 | 0.95 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL974189 | 0.95 | PDE5A (0.61) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12823560 | 0.93 | PDE5A (0.64) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12823228 | 0.93 | PDE5A (0.64) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12824053 | 0.93 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL974752 | 0.93 | PDE5A (0.62) | PDE5APDE1APDE1BPDE1CPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090041675-A1 | Organic compounds | TRIFILIEFF ALEXANDRE | 2009-02-12 | — | — | US | claimed |
| EP-1890699-A1 | INDACTEROL DERIVATIVES AND PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF AIRWAY DISEASES | Novartis AG (CH) | 2008-02-27 | — | — | EP | claimed |
| WO-2006128675-A1 | INDACTEROL DERIVATIVES AND PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | claimed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| EP-2295436-A1 | 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors | Bayer Schering Pharma AG (DE) | 2011-03-16 | — | — | EP | disclosed |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | US | disclosed |
| US-7704999-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7704999-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7696206-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20080085897-A1 | Use of 2-alkoxyphenyl-substituted imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2008-04-10 | — | — | US | disclosed |
| US-20080085897-A1 | Use of 2-alkoxyphenyl-substituted imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2008-04-10 | — | — | US | disclosed |
| EP-1890699-A1 | INDACTEROL DERIVATIVES AND PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF AIRWAY DISEASES | Novartis AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-7314871-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension | BAYER AKTIENGESELLSCHAFT (DE) | 2008-01-01 | — | — | US | disclosed |
| US-7314871-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension | BAYER AKTIENGESELLSCHAFT (DE) | 2008-01-01 | — | — | US | disclosed |
| US-20070299088-A1 | Novel Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives | BAYER HEALTHCARE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299088-A1 | Novel Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives | BAYER HEALTHCARE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| WO-2006128675-A1 | INDACTEROL DERIVATIVES AND PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006015715-A1 | NOVEL USES OF 2-PHENYL-SUBSTITUTED IMIDAZOTRIAZINONE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299088-A1 | Novel Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives | PDE5A, PDE2A, PDE3B | PDE5A 1/4885PDE1A 11/4885PDE1B 13/4885 |
| US-20090041675-A1 | Organic compounds | PDE12, PDE5A, RXFP4 | PDE5A 2/4885PDE1A 36/4885PDE1B 34/4885 |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
| US-20080085897-A1 | Use of 2-alkoxyphenyl-substituted imidazotriazinones | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 24/4885PDE1B 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.